Polyclonal Antibody to Tumor Necrosis Factor Receptor Superfamily, Member 10B (TNFRSF10B)
| Code | Size | Price |
|---|
| PAA818Mu01-20ul | 20ul | £82.00 |
Quantity:
| PAA818Mu01-100ul | 100ul | £152.00 |
Quantity:
| PAA818Mu01-200ul | 200ul | £204.00 |
Quantity:
| PAA818Mu01-1ml | 1ml | £464.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Mouse
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
CD262; TNFRSF10B; KILLER; TRAILR2; TRICK2; TRICK2A; TRICK2B; TRICKB; ZTNFR9; Death receptor 5; TNF-related apoptosis-inducing ligand receptor 2; Tumor Necrosis Factor Receptor Superfamily, Member 10B
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Death receptor 5
Reactivity:
Hu;Po;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.2-2ug/mL<br/>Immunohistochemistry: 2-20ug/mL<br/>Immunocytochemistry: 2-20ug/mL<br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Tumor Necrosis Factor Receptor Superfamily, Member 10B (TNFRSF10B) | RPA818Mu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||